Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial | Infectious Diseases | JAMA

This open-label randomized trial compares the effect of remdesivir (5 or 10 days) vs standard care on clinical status 11 days after treatment initiation among p

Related Keywords

United States ,Wuhan ,Hubei ,China ,Helsinki ,Eteläuomen Läi ,Finland ,Soriano Viladomiu ,Le Turnier ,Glaxosmithkline Vii ,Bristol Meyers Squibb ,Dianam Brainard ,Sanyal Bio ,Group Information ,Pfizer ,European Medicines Agency ,Boehringer Ingelheim ,Laboratory Monitoring ,European Medicines Agency For Europe ,Institute Inc ,Novartis ,National Institute Of Allergy ,Drug Administration For The United States ,Microsoft ,Novo Nordisk ,Gilead Sciences ,Virginia Commonwealth University ,Drug Administration ,Allergan ,Emergency Use Authorization ,Clinical Practice ,Microsoft Excel ,Hoc Analyses ,End Point ,Efficacy End Points ,Secondary End Point ,Foster City ,Drs Brainard ,Interest Disclosures ,Merck Sharp ,Second Genome ,General Electric ,Virginia Commonwealth ,National Institute ,Infectious Diseases ,Drs Sengupta ,